Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy

A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy

This study is designed to demonstrate the efficacy and to assess the safety of cinacalcet for the reduction of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy is indicated on the basis of an elevated corrected total serum calcium, but who are unable to undergo parathyroidectomy.

Study Overview

• Status: Completed
• Conditions: Hyperparathyroidism, Primary; Hypercalcemia
• Intervention / Treatment: Drug: Cinacalcet; Drug: Placebo

Detailed Description

The study will consist of a 30-day screening phase, a 12-week placebo-controlled dose-titration phase, and a 16-week placebo-controlled efficacy assessment phase (EAP). Participants who complete 28 weeks on study will continue into an open-label safety extension phase for 24 weeks of investigational cinacalcet treatment.

• Study Type: Interventional
• Enrollment (Actual): 67
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Randwick, New South Wales, Australia, 2031
      • Research Site
    • St Leonards, New South Wales, Australia, 2065
      • Research Site
  • Victoria
    • Footscray, Victoria, Australia, 3011
      • Research Site
    • Geelong, Victoria, Australia, 3220
      • Research Site
  • Western Australia
    • Nedlands, Western Australia, Australia, 6009
      • Research Site
• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2N 4Z6
      • Research Site
  • Ontario
    • London, Ontario, Canada, N6A 4V2
      • Research Site
    • Oakville, Ontario, Canada, L6J 1X8
      • Research Site
    • Toronto, Ontario, Canada, M5C 2T2
      • Research Site
• Hungary
  • Budapest, Hungary, 1083
    • Research Site
  • Budapest, Hungary, 1088
    • Research Site
  • Budapest, Hungary, 1113
    • Research Site
  • Szeged, Hungary, 6720
    • Research Site
• Poland
  • Warszawa, Poland, 02-097
    • Research Site
  • Warszawa, Poland, 02-507
    • Research Site
  • Warszawa, Poland, 01-809
    • Research Site
• Portugal
  • Coimbra, Portugal, 3000-075
    • Research Site
  • Lisboa, Portugal, 1649-035
    • Research Site
  • Lisboa, Portugal, 1350-179
    • Research Site
• Russian Federation
  • Moscow, Russian Federation, 117036
    • Research Site
  • Moscow, Russian Federation, 119034
    • Research Site
  • Moscow, Russian Federation, 129110
    • Research Site
  • Rostov-na-Dony, Russian Federation, 344022
    • Research Site
  • Saint Petersburg, Russian Federation, 197341
    • Research Site
  • Yaroslavl, Russian Federation, 150003
    • Research Site
• United States
  • California
    • Lake Forest, California, United States, 92630
      • Research Site
    • Lancaster, California, United States, 93534
      • Research Site
    • Los Gatos, California, United States, 95032
      • Research Site
    • Mission Viejo, California, United States, 92691
      • Research Site
    • Orange, California, United States, 92869
      • Research Site
    • San Diego, California, United States, 92124
      • Research Site
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Research Site
  • District of Columbia
    • Washington, District of Columbia, United States, 20010
      • Research Site
  • Florida
    • Aventura, Florida, United States, 33180
      • Research Site
    • Clearwater, Florida, United States, 33756
      • Research Site
    • Jacksonville, Florida, United States, 32204
      • Research Site
    • Miami, Florida, United States, 33145
      • Research Site
    • Pembroke Pines, Florida, United States, 33028
      • Research Site
    • Weston, Florida, United States, 33331
      • Research Site
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Research Site
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Research Site
  • Louisiana
    • Kenner, Louisiana, United States, 70065
      • Research Site
    • New Orleans, Louisiana, United States, 70121
      • Research Site
  • Michigan
    • Detroit, Michigan, United States, 48236
      • Research Site
  • New York
    • New York, New York, United States, 10032
      • Research Site
  • North Carolina
    • Morehead City, North Carolina, United States, 28557
      • Research Site
  • Ohio
    • Columbus, Ohio, United States, 43210-1296
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• age ≥ 18 years
• diagnosis of primary hyperparathyroidism (HPT)

• subjects must have the following laboratory values:

  1. local/historical laboratory result showing a corrected total serum calcium > 1 mg/dL (0.25 mmol/L) above the upper limit of normal and

     ≤ 12.5 mg/dL (3.12 mmol/L) within the past 12 months, and

     • local/historical laboratory result showing a plasma parathyroid horone (PTH) > 75% of upper limit of normal within the past 12 months, and
     • one central laboratory draw at the screen visit showing a corrected total serum calcium > 11.3 mg/dL (2.82 mmol/L) and ≤ 12.5 mg/dL (3.12 mmol/L), and
     • one central laboratory draw at the screen visit showing a plasma PTH > 55 pg/mL (5.8 pmol/L) OR

  2. two central laboratory draws performed during the screening period at least 7 days apart, showing a

     • corrected total serum calcium > 11.3 mg/dL (2.82 mmol/L) and ≤ 12.5 mg/dL (3.12 mmol/L), and
     • plasma PTH > 55 pg/mL (5.8 pmol/L)

• not able to undergo parathyroidectomy for ≥ 1 of the following reasons:

  • failed parathyroidectomy
  • comorbid conditions contraindicating parathyroidectomy
  • parathyroidectomy not considered appropriate or is not feasible by primary physician and subject
• before any study-specific procedure is performed, the appropriate written informed consent must be obtained

Exclusion Criteria:

• symptoms attributable to hypercalcemia, requiring immediate medical intervention, as judged by the investigator (including acute kidney stone, nausea and vomiting requiring intravenous hydration, confusion, lethargy, stupor, or coma)
• unstable medical condition, defined as having been hospitalized within 30 days before the date of informed consent, or otherwise unstable in the judgment of the investigator
• administration of drugs that increase serum calcium concentration, including but not limited to thiazide diuretics or lithium
• initiated bisphosphonate therapy or changed bisphosphonate dose within 12 weeks before the date of informed consent
• current administration of drugs for ventricular arrhythmia
• unable to provide informed consent, or is at risk for poor compliance with study procedures
• currently enrolled in another investigational device or drug study(s), or completed such study within 30 days before the date of informed consent
• known hypersensitivity to or unable to tolerate cinacalcet
• received treatment with cinacalcet within 60 days before the date of informed consent
• history of seizures or an adjustment of anti-seizure medication within 12 weeks before the date of informed consent
• family history or diagnosis a genetic syndrome, such as familial benign hypocalciuric hypercalcemia (FBHH) or multiple endocrine neoplasia type 1 (MEN1) and type 2 (MEN2), where primary HPT is one of the clinical manifestations of familial benign hypocalciuric hypercalcemia (FBHH)
• refused to use highly effective contraceptive measures (as determined by the investigator) throughout the study
• pregnant or breastfeeding

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cinacalcet; Participants received cinacalcet at a starting dose of 30 mg orally BID and were eligible for a dose titration once every 3 weeks during the 12-week dose-titration phase based on corrected total serum calcium concentration and safety assessments. Participants continued to receive cinacalcet for another 16 weeks during the efficacy assessment phase and then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.	Drug: Cinacalcet; Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).; Other Names: Mimpara; Sensipar
Placebo Comparator: Placebo; Participants received placebo orally twice a day (BID) for 12 weeks during the dose titration phase and for another 16 weeks during the efficacy assessment phase. Participants then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.	Drug: Cinacalcet; Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).; Other Names: Mimpara; Sensipar; Drug: Placebo; Administered orally following the same tiitration regimen as the experimental arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants With Mean Corrected Total Serum Calcium Concentration ≤ 10.3 mg/dL (2.57 mmol/L) During the EAP	Efficacy assessment phase (study visits at Weeks 16, 20, 24, and 28)

Secondary Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants With a ≥ 1 mg/dL (0.25 mmol/L) Decrease From Baseline in Mean Corrected Total Serum Calcium Concentration During the EAP	Baseline and the EAP (mean of Weeks 16, 20, 24, and 28)
Percent Change From Baseline in Corrected Total Serum Calcium Concentration During the EAP	Baseline and the EAP (mean of Weeks 16, 20, 24, and 28)
Percent Change From Baseline in Plasma Parathyroid Hormone Level During the EAP	Baseline and the EAP (mean of Weeks 16, 20, 24, and 28)

Collaborators and Investigators

• Sponsor: Amgen

Publications and helpful links

General Publications

• Khan A, Bilezikian J, Bone H, Gurevich A, Lakatos P, Misiorowski W, Rozhinskaya L, Trotman ML, Toth M. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. Eur J Endocrinol. 2015 May;172(5):527-35. doi: 10.1530/EJE-14-0877. Epub 2015 Jan 30.

Helpful Links

• AmgenTrials clinical trials website

Study record dates

Study Major Dates

• Study Start (Actual): March 10, 2010
• Primary Completion (Actual): July 12, 2012
• Study Completion (Actual): December 21, 2012

Study Registration Dates

• First Submitted: September 10, 2009
• First Submitted That Met QC Criteria: September 10, 2009
• First Posted (Estimate): September 11, 2009

Study Record Updates

• Last Update Posted (Actual): October 17, 2018
• Last Update Submitted That Met QC Criteria: September 20, 2018
• Last Verified: September 1, 2018

More Information

Terms related to this study

• Keywords: Hypercalcemia; Primary hyperparathyroidism; Parathyroidectomy
• Additional Relevant MeSH Terms: Metabolic Diseases; Endocrine System Diseases; Parathyroid Diseases; Calcium Metabolism Disorders; Water-Electrolyte Imbalance; Hyperparathyroidism; Hyperparathyroidism, Primary; Hypercalcemia; Physiological Effects of Drugs; Hormones, Hormone Substitutes, and Hormone Antagonists; Hormone Antagonists; Calcium-Regulating Hormones and Agents; Calcimimetic Agents; Cinacalcet
• Other Study ID Numbers: 20070277